Marta Valente Clariano

Ms. Marta Valente Clariano

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RCRita Capela
Rita Capela
RFRita Félix
Rita Félix
MCMarta Valente Clariano
Marta Valente Clariano
DNDiogo Nunes
Diogo Nunes
MPMaria Jesus Perry
Maria Jesus Perry
FLFrancisca Lopes
Francisca Lopes
Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a disease that, although preventable and curable, remains a global epidemic due to the emergence of resistance and a latent form responsible for a long period of treatment. Drug discovery in TB is a challenging task due to the heterogeneity of the disease, the emergence of resistance, and uncomplete knowledge of the pathophysiology of the disease. The limited permeability of the cell wall and the presence of multiple efflux pumps remain a major barrier to achieve effective intracellular drug accumulation. While the complete genome sequence of Mtb has been determined and several potential protein targets have been validated, the lack of adequate models for in vitro and in vivo studies is a limiting factor in TB drug discovery programs. In current therapeutic regimens, less than 0.5% of bacterial proteins are targeted during the biosynthesis of the cell wall and the energetic metabolism of two of the most important processes exploited for TB chemotherapeutics. This review provides an overview on the current challenges in TB drug discovery and emerging Mtb druggable proteins, and explains how chemical probes for protein profiling enabled the identification of new targets and biomarkers, paving the way to disruptive therapeutic regimens and diagnostic tools.

6 March 2023 in Chemistry & Biodiversity
Verified
Journal Article
Open access
MCMarta Valente Clariano
Marta Valente Clariano
VMVanda Marques
Vanda Marques
JVJoão Vaz
João Vaz
SASalma Awam
Salma Awam
MAMarta B. Afonso
Marta B. Afonso
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Curcumin has a plethora of biological properties, making this compound potentially effective in the treatment of several diseases, including cancer. However, curcumin clinical use is compromised by its poor pharmacokinetics, being crucial to find novel analogs with better pharmacokinetic and pharmacological properties. Here, we aimed to evaluate the stability, bioavailability and pharmacokinetic profiles of monocarbonyl analogs of curcumin. A small library of monocarbonyl analogs of curcumin 1a–q was synthesized. Lipophilicity and stability in physiological conditions were both assessed by HPLC‐UV, while two different methods assessed the electrophilic character of each compound monitored by NMR and by UV‐spectroscopy. The potential therapeutic effect of the analogs 1a–q was evaluated in human colon carcinoma cells and toxicity in immortalized hepatocytes. Our results showed that the curcumin analog 1e is a promising agent against colorectal cancer, with improved stability and efficacy/safety profile.

2 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
RCRita Capela
Rita Capela
RFRita Félix
Rita Félix
MCMarta Valente Clariano
Marta Valente Clariano
DNDiogo Nunes
Diogo Nunes
MPMaria Jesus Perry
Maria Jesus Perry
FLFrancisca Lopes
Francisca Lopes
Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a disease that alt-hough preventable and curable, remains a global epidemic due to the emergence of resistance and a latent form responsible for a long period of treatment. Drug discovery in TB is a challenging task due to the heterogeneity of the disease, the emergence of resistance and an uncomplete knowledge of the pathophysiology of the disease. The limited permeability of the cell wall and the presence of multiple efflux pumps remain a major barrier to achieve effective intracellular drug accumulation. While the complete genome sequence of Mtb has been determined and several potential protein targets have been validated, the lack of adequate models for in vitro and in vivo studies is a limit-ing factor in TB drug discovery programs. In current therapeutic regimens, less than 0.5% of bac-terial proteins are targeted being the biosynthesis of the cell wall and the energetic metabolism two of the most important processes exploited for TB chemotherapeutics. This review provides an overview on the current challenges in TB drug discovery and emerging Mtb druggable proteins, and how chemical probes for protein profiling enabled the identification of new targets and bi-omarkers, paving the way to disruptive therapeutic regimens and diagnostic tools.

3 June 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MCMarta Valente Clariano
Marta Valente Clariano
DNDiogo Nunes
Diogo Nunes
DCDaniela Canudo
Daniela Canudo
DMDaniela Maçãs
Daniela Maçãs
BCBruno J. L. Castro
Bruno J. L. Castro
FLFrancisca Lopes
Francisca Lopes